🇺🇸 FDA
Pipeline program

AUTO3 (CD19/22 CAR T cells

AUTO3-PA1

Phase 2 mab completed

Quick answer

AUTO3 (CD19/22 CAR T cells for B Acute Lymphoblastic Leukemia is a Phase 2 program (mab) at Autolus Therapeutics plc with 1 ClinicalTrials.gov record(s).

Program details

Company
Autolus Therapeutics plc
Indication
B Acute Lymphoblastic Leukemia
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials